Edition:
United States

Inflarx NV (IFRX.OQ)

IFRX.OQ on NASDAQ Stock Exchange Global Select Market

35.32USD
18 Jan 2019
Change (% chg)

-- (--)
Prev Close
$35.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
12,590
52-wk High
$42.79
52-wk Low
$20.31

Latest Key Developments (Source: Significant Developments)

Inflarx N.V. Reports Third Quarter 2018 Financial & Operating Results
Wednesday, 21 Nov 2018 08:30am EST 

Nov 21 (Reuters) - Inflarx NV ::INFLARX N.V. REPORTS THIRD QUARTER 2018 FINANCIAL & OPERATING RESULTS.Q3 LOSS PER SHARE EUR 0.30.Q3 EARNINGS PER SHARE VIEW EUR -0.36 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS AND SECURITIES AND OTHER INVESTMENTS OF EUR 162.1 MILLION.  Full Article

Inflarx NV Q2 Loss Per Share EUR 0.10
Thursday, 9 Aug 2018 07:00am EDT 

Aug 9 (Reuters) - Inflarx NV ::INFLARX N.V. REPORTS SECOND QUARTER 2018 FINANCIAL & OPERATING RESULTS.Q2 LOSS PER SHARE EUR 0.10.Q2 EARNINGS PER SHARE VIEW EUR -0.34 -- THOMSON REUTERS I/B/E/S.CASH POSITION APPROXIMATELY EUR 156.1 MILLION (US$182.2 MILLION) AS OF JUNE 30, 2018.  Full Article

InflaRx Receives IND Approval From FDA To Start Phase II Clinical Trial Of IFX-1
Thursday, 28 Jun 2018 07:30am EDT 

June 28 (Reuters) - Inflarx NV ::INFLARX RECEIVES IND APPROVAL FROM THE FDA TO START ITS PHASE II CLINICAL TRIAL OF IFX-1 IN ANCA-ASSOCIATED VASCULITIS.INFLARX NV - OPEN IND WILL ALLOW INFLARX TO START PLANNED PHASE II STUDY TO DETERMINE SAFETY AND EFFICACY OF IFX-1.  Full Article

InflaRx Full Year 2017 Financial & Operating Results
Thursday, 29 Mar 2018 07:00am EDT 

March 29 (Reuters) - InflaRx NV ::INFLARX FULL YEAR 2017 FINANCIAL & OPERATING RESULTS.INFLARX NV - CASH AND CASH EQUIVALENTS TOTALED EUR 123.3 MILLION AS OF DECEMBER 31, 2017 COMPARED TO EUR 29.1 MILLION AS OF DECEMBER 31, 2016.  Full Article

Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa
Tuesday, 9 Jan 2018 08:56am EST 

Jan 9 (Reuters) - Inflarx Nv ::INFLARX RECEIVES IND ACCEPTANCE TO PROCEED WITH A PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA.INFLARX NV - ‍INTENDS TO INITIATE THE STUDY ON IFX-1 IN Q1 OF 2018​.  Full Article

Ra Capital Management Reports 12.3 Pct Passive Stake In Inflarx Nv
Monday, 11 Dec 2017 05:33pm EST 

Dec 11 (Reuters) - Inflarx Nv ::RA CAPITAL MANAGEMENT LLC REPORTS 12.3 PERCENT PASSIVE STAKE IN INFLARX NV AS OF NOVEMBER 8 - SEC FILING.  Full Article